June 26, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Coherus Biosciences Inc (NASDAQ:CHRS) shares over potential securities laws violations in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Coherus Biosciences Inc (NASDAQ:CHRS) concerning whether a series of statements regarding Coherus Biosciences business, its prospects and its operations were materially false and misleading at the time they were made.

Redwood City, CA based Coherus BioSciences, Inc. is a late-stage clinical biologics platform company that is engaged in the business of developing and commercializing biosimilar products.

Shares of Coherus Biosciences Inc (NASDAQ:CHRS) reached in 2015 as high as $36.52 per share. Coherus Biosciences Inc reported that its annual Total Revenue rose from $30.04 million in 2015 to $190.11 million in 2016 and that its Net loss declined from $223.26 million in 2015 to $127.34 million in 2016.

On June 12, 2017, Coherus Biosciences Inc announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for its biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate, under the 351(k) pathway.